HOME >> BIOLOGY >> NEWS
Joslin researchers identify key molecule in Type 1 diabetes progression

BOSTON - Why do some people seem to develop type 1 diabetes rapidly while in others it may take years to develop? A new study by Joslin Diabetes Center researchers reveals one of the key biochemical pathways that determines whether type 1 diabetes will remain in its early stages or progress to full-blown disease, possibly explaining why some people develop type 1 diabetes more rapidly than others. The study was published earlier this month in The Journal of Experimental Medicine by a team from Joslin's Immunology and Immunogenetics research section.

For many years scientists have known that type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly launches an attack on the insulin-producing beta cells of the pancreas. At an early stage in this process, white blood cells called T-cells invade the islets of Langerhans of the pancreas, where the beta cells reside (a condition known as "insulitis"). Yet, in both mice and humans, insulitis does not always progress to full-blown type 1 diabetes. For years, researchers have been trying to determine why insulitis sometimes leads to diabetes (so-called "destructive" insulitis) and sometimes does not ("respectful" insulitis). They know that certain T-cells called T effector cells promote destructive insulitis, and other T-cells called regulatory T-cells favor respectful insulitis. Yet, no one knows exactly what causes the balance of power to shift between these two types of cells to cause diabetes.

To study this question, Anne E. Herman, Ph.D., Diane Mathis, Ph.D., and Christophe Benoist, M.D., Ph.D., of the Section on Immunology and Immunogenetics at Joslin Diabetes Center in Boston studied insulitis lesions in a certain strain of genetically engineered mice called BCD2.5 mice. These mice develop insulitis, but a very respectful form, such that diabetes does not follow until months later, or, in some, never. The researchers discovered that both effector and r
'"/>

Contact: Marge Dwyer
marjorie.dwyer@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
23-Jun-2004


Page: 1 2 3

Related biology news :

1. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
2. Joslin researchers clarify mechanisms for beta-cell formation
3. Joslin President awarded medal from international diabetes organization
4. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
5. New imaging technology at Joslin shown to detect early signs of type 1 diabetes
6. Joslin Diabetes Center launches research section on developmental and stem cell biology
7. Joslin Diabetes Center releases new low impact exercise video
8. As obesity skyrockets, Joslin Diabetes Center urges action to stem the tide of type 2 diabetes
9. Belgian researchers explore revolutionary approach to angiogenesis
10. Award winning researchers reveal potential new role for Glivec
11. $7.5 Million grant to Yale researchers for role of viruses in cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... , ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, ... list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions ... reported three-year revenue growth of 71 percent. , The Inc. 5000 list represents ...
(Date:8/21/2020)... ... 2020 , ... NDA Partners Chairman Carl Peck, MD ... expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical investigator ... career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and anti-infective ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
(Date:7/31/2020)... (PRWEB) , ... July 30, ... ... of cloud-based software for the life sciences industry, today announced the release ... platform designed specifically for Medical Science Liaisons (MSLs) and other field medical ...
(Date:7/18/2020)... ... 2020 , ... “We are thrilled to deliver this new technology to the ... its kind on the market and we were pleased that the IFT jury recognized ... cultured ingredients, creating a natural way to extend the shelf life and improve the ...
Breaking Biology Technology:
Cached News: